Reduced dorso-lateral prefrontal cortex in treatment resistant schizophrenia

Abstract Background Treatment resistance affects up to one third of patients with schizophrenia (SCZ). A better understanding of its biological underlying processes could improve treatment. The aim of this study was to compare cortical thickness between non-resistant SCZ (NR-SCZ), treatment-resistan...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Schizophrenia research 2013-08, Vol.148 (1), p.81-86
Hauptverfasser: Zugman, André, Gadelha, Ary, Assunção, Idaiane, Sato, João, Ota, Vanessa K, Rocha, Deyvis L, Mari, Jair J, Belangero, Sintia I, Bressan, Rodrigo A, Brietzke, Elisa, Jackowski, Andrea P
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 86
container_issue 1
container_start_page 81
container_title Schizophrenia research
container_volume 148
creator Zugman, André
Gadelha, Ary
Assunção, Idaiane
Sato, João
Ota, Vanessa K
Rocha, Deyvis L
Mari, Jair J
Belangero, Sintia I
Bressan, Rodrigo A
Brietzke, Elisa
Jackowski, Andrea P
description Abstract Background Treatment resistance affects up to one third of patients with schizophrenia (SCZ). A better understanding of its biological underlying processes could improve treatment. The aim of this study was to compare cortical thickness between non-resistant SCZ (NR-SCZ), treatment-resistant SCZ (TR-SCZ) patients and healthy controls (HC). Methodology Structural MRI scans were obtained from 3 groups of individuals: 61 treatment resistant SCZ individuals, 67 non-resistant SCZ and 80 healthy controls. Images were analyzed using cortical surface modelling (implemented in freesurfer package) to identify group differences in cortical thickness. Statistical significant differences were identified using Monte-Carlo simulation method with a corrected p-cluster < 0.01. Results Patients in the TR-SCZ group showed a widespread reduction in cortical thickness in frontal, parietal, temporal and occipital regions bilaterally. NR-SCZ group had reduced cortex in two regions (left superior frontal cortex and left caudal middle frontal cortex). TR-SCZ group also showed decreased thickness in the left dorsolateral prefrontal cortex (DLPFC) when compared with patients from NR-SCZ group. Conclusions The reduction in cortical thickness in DLPFC indicates a more severe form of the disease or a specific finding for this group. Alterations in this region should be explored as a putative marker for treatment resistance. Prospective studies, with individuals being followed from first episode psychosis until refractoriness is diagnosed, are needed to clarify these hypotheses.
doi_str_mv 10.1016/j.schres.2013.05.002
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1417535094</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0920996413002570</els_id><sourcerecordid>1417535094</sourcerecordid><originalsourceid>FETCH-LOGICAL-c513t-86250ac80c4b7b7dfe8b05e0b6494050acc49e3c657ac6f639ca51f69ff151ed3</originalsourceid><addsrcrecordid>eNqFkU2LFDEQhoMo7uzqPxDpi-Cl20rna3IRZFFXGBD8OId0uhoz9iRjkl5cf71pZ1Tw4ikFeavet54i5AmFjgKVL_Zddl8S5q4HyjoQHUB_j2yoUKztBej7ZAO6h1ZryS_IZc57AKAC1ENy0TPVUy3lhuw-4Lg4HJsxphzb2RZMdm6OCacUQ6mli6ng98aHpiS05YChNNXW52JrVTP4H_FYgwRvH5EHk50zPj6_V-Tzm9efrm_a3fu3765f7VonKCvtVtZ81m3B8UENapxwO4BAGCTXHNYvxzUyJ4WyTk6SaWcFnaSeJioojuyKPD_NPab4bcFczMFnh_NsA8YlG8qpEqwy4FXKT1KXYs51K3NM_mDTnaFgVo5mb04czcrRgDCVY217enZYhgOOf5p-g6uCZ2eBzc7OU7LB-fxXpyRj_Jfu5UmHlcetx1TdPIZK3Cd0xYzR_y_JvwPc7IOvnl_xDvM-LilU1oaa3BswH9ebryenrHYLBewnEouorg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1417535094</pqid></control><display><type>article</type><title>Reduced dorso-lateral prefrontal cortex in treatment resistant schizophrenia</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Zugman, André ; Gadelha, Ary ; Assunção, Idaiane ; Sato, João ; Ota, Vanessa K ; Rocha, Deyvis L ; Mari, Jair J ; Belangero, Sintia I ; Bressan, Rodrigo A ; Brietzke, Elisa ; Jackowski, Andrea P</creator><creatorcontrib>Zugman, André ; Gadelha, Ary ; Assunção, Idaiane ; Sato, João ; Ota, Vanessa K ; Rocha, Deyvis L ; Mari, Jair J ; Belangero, Sintia I ; Bressan, Rodrigo A ; Brietzke, Elisa ; Jackowski, Andrea P</creatorcontrib><description>Abstract Background Treatment resistance affects up to one third of patients with schizophrenia (SCZ). A better understanding of its biological underlying processes could improve treatment. The aim of this study was to compare cortical thickness between non-resistant SCZ (NR-SCZ), treatment-resistant SCZ (TR-SCZ) patients and healthy controls (HC). Methodology Structural MRI scans were obtained from 3 groups of individuals: 61 treatment resistant SCZ individuals, 67 non-resistant SCZ and 80 healthy controls. Images were analyzed using cortical surface modelling (implemented in freesurfer package) to identify group differences in cortical thickness. Statistical significant differences were identified using Monte-Carlo simulation method with a corrected p-cluster &lt; 0.01. Results Patients in the TR-SCZ group showed a widespread reduction in cortical thickness in frontal, parietal, temporal and occipital regions bilaterally. NR-SCZ group had reduced cortex in two regions (left superior frontal cortex and left caudal middle frontal cortex). TR-SCZ group also showed decreased thickness in the left dorsolateral prefrontal cortex (DLPFC) when compared with patients from NR-SCZ group. Conclusions The reduction in cortical thickness in DLPFC indicates a more severe form of the disease or a specific finding for this group. Alterations in this region should be explored as a putative marker for treatment resistance. Prospective studies, with individuals being followed from first episode psychosis until refractoriness is diagnosed, are needed to clarify these hypotheses.</description><identifier>ISSN: 0920-9964</identifier><identifier>EISSN: 1573-2509</identifier><identifier>DOI: 10.1016/j.schres.2013.05.002</identifier><identifier>PMID: 23721966</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Adult ; Adult and adolescent clinical studies ; Antipsychotic Agents - therapeutic use ; Biological and medical sciences ; Cortical thickness ; Female ; Humans ; Image Processing, Computer-Assisted ; Magnetic Resonance Imaging ; Male ; Medical sciences ; MRI ; Nerve Net - drug effects ; Nerve Net - pathology ; Prefrontal Cortex - drug effects ; Prefrontal Cortex - pathology ; Psychiatry ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychoses ; Refractory ; Schizophrenia ; Schizophrenia - drug therapy ; Schizophrenia - pathology ; Treatment resistant ; Young Adult</subject><ispartof>Schizophrenia research, 2013-08, Vol.148 (1), p.81-86</ispartof><rights>Elsevier B.V.</rights><rights>2013 Elsevier B.V.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2013 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c513t-86250ac80c4b7b7dfe8b05e0b6494050acc49e3c657ac6f639ca51f69ff151ed3</citedby><cites>FETCH-LOGICAL-c513t-86250ac80c4b7b7dfe8b05e0b6494050acc49e3c657ac6f639ca51f69ff151ed3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0920996413002570$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=27633466$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23721966$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zugman, André</creatorcontrib><creatorcontrib>Gadelha, Ary</creatorcontrib><creatorcontrib>Assunção, Idaiane</creatorcontrib><creatorcontrib>Sato, João</creatorcontrib><creatorcontrib>Ota, Vanessa K</creatorcontrib><creatorcontrib>Rocha, Deyvis L</creatorcontrib><creatorcontrib>Mari, Jair J</creatorcontrib><creatorcontrib>Belangero, Sintia I</creatorcontrib><creatorcontrib>Bressan, Rodrigo A</creatorcontrib><creatorcontrib>Brietzke, Elisa</creatorcontrib><creatorcontrib>Jackowski, Andrea P</creatorcontrib><title>Reduced dorso-lateral prefrontal cortex in treatment resistant schizophrenia</title><title>Schizophrenia research</title><addtitle>Schizophr Res</addtitle><description>Abstract Background Treatment resistance affects up to one third of patients with schizophrenia (SCZ). A better understanding of its biological underlying processes could improve treatment. The aim of this study was to compare cortical thickness between non-resistant SCZ (NR-SCZ), treatment-resistant SCZ (TR-SCZ) patients and healthy controls (HC). Methodology Structural MRI scans were obtained from 3 groups of individuals: 61 treatment resistant SCZ individuals, 67 non-resistant SCZ and 80 healthy controls. Images were analyzed using cortical surface modelling (implemented in freesurfer package) to identify group differences in cortical thickness. Statistical significant differences were identified using Monte-Carlo simulation method with a corrected p-cluster &lt; 0.01. Results Patients in the TR-SCZ group showed a widespread reduction in cortical thickness in frontal, parietal, temporal and occipital regions bilaterally. NR-SCZ group had reduced cortex in two regions (left superior frontal cortex and left caudal middle frontal cortex). TR-SCZ group also showed decreased thickness in the left dorsolateral prefrontal cortex (DLPFC) when compared with patients from NR-SCZ group. Conclusions The reduction in cortical thickness in DLPFC indicates a more severe form of the disease or a specific finding for this group. Alterations in this region should be explored as a putative marker for treatment resistance. Prospective studies, with individuals being followed from first episode psychosis until refractoriness is diagnosed, are needed to clarify these hypotheses.</description><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cortical thickness</subject><subject>Female</subject><subject>Humans</subject><subject>Image Processing, Computer-Assisted</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Medical sciences</subject><subject>MRI</subject><subject>Nerve Net - drug effects</subject><subject>Nerve Net - pathology</subject><subject>Prefrontal Cortex - drug effects</subject><subject>Prefrontal Cortex - pathology</subject><subject>Psychiatry</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychoses</subject><subject>Refractory</subject><subject>Schizophrenia</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenia - pathology</subject><subject>Treatment resistant</subject><subject>Young Adult</subject><issn>0920-9964</issn><issn>1573-2509</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU2LFDEQhoMo7uzqPxDpi-Cl20rna3IRZFFXGBD8OId0uhoz9iRjkl5cf71pZ1Tw4ikFeavet54i5AmFjgKVL_Zddl8S5q4HyjoQHUB_j2yoUKztBej7ZAO6h1ZryS_IZc57AKAC1ENy0TPVUy3lhuw-4Lg4HJsxphzb2RZMdm6OCacUQ6mli6ng98aHpiS05YChNNXW52JrVTP4H_FYgwRvH5EHk50zPj6_V-Tzm9efrm_a3fu3765f7VonKCvtVtZ81m3B8UENapxwO4BAGCTXHNYvxzUyJ4WyTk6SaWcFnaSeJioojuyKPD_NPab4bcFczMFnh_NsA8YlG8qpEqwy4FXKT1KXYs51K3NM_mDTnaFgVo5mb04czcrRgDCVY217enZYhgOOf5p-g6uCZ2eBzc7OU7LB-fxXpyRj_Jfu5UmHlcetx1TdPIZK3Cd0xYzR_y_JvwPc7IOvnl_xDvM-LilU1oaa3BswH9ebryenrHYLBewnEouorg</recordid><startdate>20130801</startdate><enddate>20130801</enddate><creator>Zugman, André</creator><creator>Gadelha, Ary</creator><creator>Assunção, Idaiane</creator><creator>Sato, João</creator><creator>Ota, Vanessa K</creator><creator>Rocha, Deyvis L</creator><creator>Mari, Jair J</creator><creator>Belangero, Sintia I</creator><creator>Bressan, Rodrigo A</creator><creator>Brietzke, Elisa</creator><creator>Jackowski, Andrea P</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20130801</creationdate><title>Reduced dorso-lateral prefrontal cortex in treatment resistant schizophrenia</title><author>Zugman, André ; Gadelha, Ary ; Assunção, Idaiane ; Sato, João ; Ota, Vanessa K ; Rocha, Deyvis L ; Mari, Jair J ; Belangero, Sintia I ; Bressan, Rodrigo A ; Brietzke, Elisa ; Jackowski, Andrea P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c513t-86250ac80c4b7b7dfe8b05e0b6494050acc49e3c657ac6f639ca51f69ff151ed3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cortical thickness</topic><topic>Female</topic><topic>Humans</topic><topic>Image Processing, Computer-Assisted</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Medical sciences</topic><topic>MRI</topic><topic>Nerve Net - drug effects</topic><topic>Nerve Net - pathology</topic><topic>Prefrontal Cortex - drug effects</topic><topic>Prefrontal Cortex - pathology</topic><topic>Psychiatry</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychoses</topic><topic>Refractory</topic><topic>Schizophrenia</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenia - pathology</topic><topic>Treatment resistant</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zugman, André</creatorcontrib><creatorcontrib>Gadelha, Ary</creatorcontrib><creatorcontrib>Assunção, Idaiane</creatorcontrib><creatorcontrib>Sato, João</creatorcontrib><creatorcontrib>Ota, Vanessa K</creatorcontrib><creatorcontrib>Rocha, Deyvis L</creatorcontrib><creatorcontrib>Mari, Jair J</creatorcontrib><creatorcontrib>Belangero, Sintia I</creatorcontrib><creatorcontrib>Bressan, Rodrigo A</creatorcontrib><creatorcontrib>Brietzke, Elisa</creatorcontrib><creatorcontrib>Jackowski, Andrea P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Schizophrenia research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zugman, André</au><au>Gadelha, Ary</au><au>Assunção, Idaiane</au><au>Sato, João</au><au>Ota, Vanessa K</au><au>Rocha, Deyvis L</au><au>Mari, Jair J</au><au>Belangero, Sintia I</au><au>Bressan, Rodrigo A</au><au>Brietzke, Elisa</au><au>Jackowski, Andrea P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reduced dorso-lateral prefrontal cortex in treatment resistant schizophrenia</atitle><jtitle>Schizophrenia research</jtitle><addtitle>Schizophr Res</addtitle><date>2013-08-01</date><risdate>2013</risdate><volume>148</volume><issue>1</issue><spage>81</spage><epage>86</epage><pages>81-86</pages><issn>0920-9964</issn><eissn>1573-2509</eissn><abstract>Abstract Background Treatment resistance affects up to one third of patients with schizophrenia (SCZ). A better understanding of its biological underlying processes could improve treatment. The aim of this study was to compare cortical thickness between non-resistant SCZ (NR-SCZ), treatment-resistant SCZ (TR-SCZ) patients and healthy controls (HC). Methodology Structural MRI scans were obtained from 3 groups of individuals: 61 treatment resistant SCZ individuals, 67 non-resistant SCZ and 80 healthy controls. Images were analyzed using cortical surface modelling (implemented in freesurfer package) to identify group differences in cortical thickness. Statistical significant differences were identified using Monte-Carlo simulation method with a corrected p-cluster &lt; 0.01. Results Patients in the TR-SCZ group showed a widespread reduction in cortical thickness in frontal, parietal, temporal and occipital regions bilaterally. NR-SCZ group had reduced cortex in two regions (left superior frontal cortex and left caudal middle frontal cortex). TR-SCZ group also showed decreased thickness in the left dorsolateral prefrontal cortex (DLPFC) when compared with patients from NR-SCZ group. Conclusions The reduction in cortical thickness in DLPFC indicates a more severe form of the disease or a specific finding for this group. Alterations in this region should be explored as a putative marker for treatment resistance. Prospective studies, with individuals being followed from first episode psychosis until refractoriness is diagnosed, are needed to clarify these hypotheses.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>23721966</pmid><doi>10.1016/j.schres.2013.05.002</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0920-9964
ispartof Schizophrenia research, 2013-08, Vol.148 (1), p.81-86
issn 0920-9964
1573-2509
language eng
recordid cdi_proquest_miscellaneous_1417535094
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Adult
Adult and adolescent clinical studies
Antipsychotic Agents - therapeutic use
Biological and medical sciences
Cortical thickness
Female
Humans
Image Processing, Computer-Assisted
Magnetic Resonance Imaging
Male
Medical sciences
MRI
Nerve Net - drug effects
Nerve Net - pathology
Prefrontal Cortex - drug effects
Prefrontal Cortex - pathology
Psychiatry
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychoses
Refractory
Schizophrenia
Schizophrenia - drug therapy
Schizophrenia - pathology
Treatment resistant
Young Adult
title Reduced dorso-lateral prefrontal cortex in treatment resistant schizophrenia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T03%3A30%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reduced%20dorso-lateral%20prefrontal%20cortex%20in%20treatment%20resistant%20schizophrenia&rft.jtitle=Schizophrenia%20research&rft.au=Zugman,%20Andr%C3%A9&rft.date=2013-08-01&rft.volume=148&rft.issue=1&rft.spage=81&rft.epage=86&rft.pages=81-86&rft.issn=0920-9964&rft.eissn=1573-2509&rft_id=info:doi/10.1016/j.schres.2013.05.002&rft_dat=%3Cproquest_cross%3E1417535094%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1417535094&rft_id=info:pmid/23721966&rft_els_id=S0920996413002570&rfr_iscdi=true